What is Crohn’s Disease?
08-12-2024
06:30 PM
1 min read
Overview:
In a recent study published, researchers assess the efficacy and safety of filgotinib, a Janus kinase (JAK) 1 preferential inhibitor, as induction and maintenance therapy in patients with moderately to severely active Crohn's disease.
About Crohn’s Disease:
- It is a type of inflammatory bowel disease (IBD).
- It is a chronic, or long-term condition that causes inflammation in the digestive tract.
- Causes: It is not clear what causes Crohn’s disease. Experts suggest that it may stem from an abnormal reaction of the immune system.
- Although it typically starts in childhood or early adulthood, Crohn’s disease can develop at any age.
- Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people, most commonly the small intestine.
- Symptoms: The most common symptoms of Crohn’s disease are diarrhoea, cramping and pain in your abdomen, anaemia, altered appetite, and weight loss.
- Treatment: There's no known cure for Crohn's disease, but therapies can greatly reduce its signs and symptoms.
Q1: What is filgotinib?
Filgotinib is a medication used primarily in the treatment of inflammatory conditions such as rheumatoid arthritis (RA), ulcerative colitis (UC), and Crohn's disease. It is classified as a Janus kinase (JAK) inhibitor, targeting specific pathways involved in the immune response.
News: Filgotinib offers new promise for managing Crohn’s disease